WO2018087143A3 - Anti-pd-1 antibodies - Google Patents
Anti-pd-1 antibodies Download PDFInfo
- Publication number
- WO2018087143A3 WO2018087143A3 PCT/EP2017/078595 EP2017078595W WO2018087143A3 WO 2018087143 A3 WO2018087143 A3 WO 2018087143A3 EP 2017078595 W EP2017078595 W EP 2017078595W WO 2018087143 A3 WO2018087143 A3 WO 2018087143A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibodies
- relates
- immunoconjugates
- bind
- therapeutic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention relates to antibodies that bind to PD-1. The invention also relates to immunoconjugates and compositions comprising such antibodies. The invention also provides methods of producing such antibodies. The invention further provides the use of such antibodies for therapeutic and diagnostic purposes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201990978A EA201990978A1 (en) | 2016-11-08 | 2017-11-08 | ANTIBODIES AGAINST PD-1 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201618833 | 2016-11-08 | ||
GB1618833.6 | 2016-11-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2018087143A2 WO2018087143A2 (en) | 2018-05-17 |
WO2018087143A3 true WO2018087143A3 (en) | 2018-12-13 |
Family
ID=60388022
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2017/078595 WO2018087143A2 (en) | 2016-11-08 | 2017-11-08 | Anti-pd-1 antibodies |
Country Status (2)
Country | Link |
---|---|
EA (1) | EA201990978A1 (en) |
WO (1) | WO2018087143A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
CA3125476A1 (en) * | 2019-01-03 | 2020-07-09 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer |
WO2021006199A1 (en) | 2019-07-05 | 2021-01-14 | 小野薬品工業株式会社 | Treatment of hematologic cancer with pd-1/cd3 dual specificity protein |
WO2021025140A1 (en) | 2019-08-08 | 2021-02-11 | 小野薬品工業株式会社 | Dual-specific protein |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016113556A1 (en) * | 2015-01-12 | 2016-07-21 | Crescendo Biologics Limited | Methods for producing optimised therapeutic molecules |
-
2017
- 2017-11-08 WO PCT/EP2017/078595 patent/WO2018087143A2/en active Application Filing
- 2017-11-08 EA EA201990978A patent/EA201990978A1/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016113556A1 (en) * | 2015-01-12 | 2016-07-21 | Crescendo Biologics Limited | Methods for producing optimised therapeutic molecules |
Non-Patent Citations (4)
Title |
---|
C. WANG ET AL: "In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates", CANCER IMMUNOLOGY RESEARCH, vol. 2, no. 9, 28 May 2014 (2014-05-28), pages 846 - 856, XP055206944, ISSN: 2326-6066, DOI: 10.1158/2326-6066.CIR-14-0040 * |
KATHLEEN M. MAHONEY ET AL: "The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma", CLINICAL THERAPEUTICS., vol. 37, no. 4, 1 April 2015 (2015-04-01), US, pages 764 - 782, XP055285031, ISSN: 0149-2918, DOI: 10.1016/j.clinthera.2015.02.018 * |
ROY L MAUTE ET AL: "Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA,, vol. 112, no. 47, 1 November 2015 (2015-11-01), pages E6506 - E6514, XP002772779, ISSN: 0027-8424, DOI: 10.1073/PNAS.1519623112 * |
TERESA C. LONGORIA ET AL: "Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma", EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, vol. 12, no. 10, 16 August 2016 (2016-08-16), GB, pages 1247 - 1253, XP055516478, ISSN: 1742-5255, DOI: 10.1080/17425255.2016.1216976 * |
Also Published As
Publication number | Publication date |
---|---|
EA201990978A1 (en) | 2019-12-30 |
WO2018087143A2 (en) | 2018-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018501177A1 (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
WO2016077397A3 (en) | Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies | |
PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
MX2022008184A (en) | Anti pd-1 and anti-lag3 antibodies for cancer treatment. | |
MX2018016364A (en) | Anti-pd-l1 antibodies. | |
MX2018012757A (en) | Agonistic antibodies that bind human cd40 and uses thereof. | |
MX2018008934A (en) | Anti-ror1 antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same. | |
PH12019500923A1 (en) | Anti-pd-1 antibodies and compositions | |
WO2016014688A3 (en) | Anti-pd-1 antibodies | |
MX2018003936A (en) | Anti-pd-1 antibodies and compositions. | |
PH12021550690A1 (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
EP4249515A3 (en) | Humanized or chimeric cd3 antibodies | |
PH12017501077A1 (en) | Compositions and methods for antibodies targeting bmp6 | |
MX2022014914A (en) | Glycan-interacting compounds and methods of use. | |
MX2022008523A (en) | Glycan-interacting compounds and methods of use. | |
PH12019502025A1 (en) | Anti-tigit antigen-binding proteins and methods of use thereof | |
WO2018087143A3 (en) | Anti-pd-1 antibodies | |
EP3492101A3 (en) | Agents for influenza neutralization | |
MX2018015265A (en) | Methods for the use of cd32b x cd79b-binding molecules in the treatment of inflammatory diseases and disorders. | |
WO2018094300A8 (en) | Anti-gitr antigen-binding proteins and methods of use thereof | |
PH12019502694A1 (en) | Anti-trkb antibodies | |
MX2018009218A (en) | Cgrp antibodies and uses thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17800783 Country of ref document: EP Kind code of ref document: A2 |